Aptevo Therapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 7, 2024
APVO$1.08-4.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes in Stockholders’ Equity
(in thousands, except share amounts, unaudited)
| Additional · Total | |||||||
|---|---|---|---|---|---|---|---|
| Common Stock · Paid-In · Accumulated · Stockholders' | |||||||
| Shares · Amount · Capital · Deficit · Equity | |||||||
| Balance at December 31, 2023 | 442,458 | $61 | $235,607 | $(223,447) | $12,221 | ||
| Common stock issued upon vesting of restricted stock units | 213 | — | — | — | — | ||
| Issuances of common stock | 231,130 | 5 | (5) | — | — | ||
| Payment in lieu of fractional shares in connection with the 1-for-44 reverse stock split effected on March 5, 2024 | (371) | — | (3) | — | (3) | ||
| Stock-based compensation | — | — | 719 | — | 719 | ||
| Net loss for the period | — | — | (6,834) | (6,834) | |||
| Balance at March 31, 2024 | 673,430 | $66 | $236,318 | $(230,281) | $6,103 | ||
| Common stock issued upon vesting of restricted stock units | 2,257 | — | — | — | — | ||
| Issuances of common stock | 3,404,978 | 3 | 3,967 | — | 3,970 | ||
| Stock-based compensation | — | — | 273 | — | 273 | ||
| Net loss for the period | — | — | — | (5,883) | (5,883) | ||
| Balance at June 30, 2024 | 4,080,665 | $69 | $240,558 | $(236,164) | $4,463 | ||
| Common stock issued upon vesting of restricted stock units | 703 | — | — | — | — | ||
| Issuances of common stock(1) | 12,969,168 | 13 | 4,424 | — | 4,437 | ||
| Warrant modification - incremental fair value | — | — | 472 | — | 472 | ||
| Stock-based compensation | — | — | 149 | — | 149 | ||
| Net loss for the period | — | — | — | (5,101) | (5,101) | ||
| Balance at September 30, 2024 | 17,050,536 | $82 | $245,603 | $(241,265) | $4,420 | ||
| Additional · Total | |||||||
| Common Stock · Paid-In · Accumulated · Stockholders' | |||||||
| Shares · Amount · Capital · Deficit · Equity (Deficit) | |||||||
| Balance at December 31, 2022 | 146,961 | $48 | $223,962 | $(206,036) | $17,974 | ||
| Common stock issued upon vesting of restricted stock units | 961 | — | (8) | — | (8) | ||
| Issuances of common stock | 16,611 | 1 | 1,601 | — | 1,602 | ||
| Stock-based compensation | — | — | 915 | — | 915 | ||
| Net income for the period | — | — | — | 2,773 | 2,773 | ||
| Balance at March 31, 2023 | 164,533 | $49 | $226,470 | $(203,263) | $23,256 | ||
| Common stock issued upon vesting of restricted stock units | 90 | — | (2) | — | (2) | ||
| Issuances of common stock | 6,818 | — | 482 | — | 482 | ||
| Stock-based compensation | — | — | 465 | — | 465 | ||
| Net loss for the period | — | — | — | (7,948) | (7,948) | ||
| Balance at June 30, 2023 | 171,441 | 49 | 227,415 | (211,211) | 16,253 | ||
| Common stock issued upon vesting of restricted stock units | 1,108 | — | — | — | — | ||
| Issuances of common stock | 50,489 | 2 | 1,197 | — | 1,199 | ||
| Issuances of pre-funded warrants | 105,725 | 5 | 3,140 | — | 3,145 | ||
| Stock-based compensation | — | — | 455 | — | 455 | ||
| Net loss for the period | — | — | — | (6,334) | (6,334) | ||
| Balance at September 30, 2023 | 328,763 | $56 | $232,207 | $(217,545) | $14,718 | ||
(1) Includes gross proceeds of $5.8 million less issuance costs of $1.3 million, which includes $0.5 million warrant modification incremental fair value.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.